FibroBiologics, Inc. (FBLG)

Market Cap	22.21M -65.4%
Revenue (ttm)	n/a
Net Income	-18.65M
EPS	-0.42
Shares Out	67.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,288,706
Open	0.3000
Previous Close	0.2829
Day's Range	0.3000 - 0.3346
52-Week Range	0.2201 - 1.5300
Beta	-0.58
Analysts	Strong Buy
Price Target	5.50 (+1,573.77%)
Earnings Date	Feb 24, 2026

About FBLG

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2024
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: FBLG
• Website: https://fibrobiologics.com

Analyst Summary

According to 2 analysts, the average rating for FBLG stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 1,573.77% from the latest price.

Price Target

$5.5

(1,573.77% upside)

Analyst Consensus: Strong Buy